Dermatitis

MIAMI BEACH, Fla. — Patients with atopic dermatitis resistant to systemic therapy, including dupilumab, may benefit from tralokinumab treatment, according to a poster presentation here.

Phase 3 results that supported the approval of roflumilast foam 0.3% for seborrheic dermatitis treatment showed that the drug was superior to vehicle for individuals aged 9 years and older in this indication, according to a study.

Icahn School of Medicine at Mount Sinai and Clinique have partnered to establish the Mount Sinai-Clinique Healthy Skin Dermatology Center, Mount Sinai announced in a press release.

Arcutis has officially launched sales for Zoryve topical foam 0.3% in the U.S. for the treatment of seborrheic dermatitis in individuals aged 9 years and older, according to a press release.

Children who were exposed to opioids prenatally faced greater risks for infection, eczema and dermatitis, and asthma, but not for allergies, anaphylaxis or autoimmune diseases, according to a study published in JAMA Network Open.

A phase 3 study subgroup analysis showed that patients with seborrheic dermatitis who cannot use topical steroids were more likely to achieve disease clearance with Zoryve topical foam vs. vehicle, Arcutis announced in a press release.

Dupixent for atopic dermatitis has received a label update from the FDA adding phase 3 efficacy and safety data, Regeneron and Sanofi announced in a press release.

According to analyses of new phase 3 data, patients with atopic dermatitis that were treated with Vtama cream 1% maintained long-term improvement even after stopping treatment, Dermavant announced in a press release.

The FDA has approved Zoryve for the treatment of seborrheic dermatitis in individuals aged 9 years and older, Arcutis announced in a press release.

The FDA has accepted the supplemental new drug application for roflumilast cream 0.15% for adults and children aged as young as 6 years with atopic dermatitis, Arcutis Biotherapeutics announced in a press release.